TMSS Medical College Journal

Background: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection showed different laboratory abnormalities among patients. We aim to investigate laboratory findings of patients infected with SARS-COV-2. Materials and Methods:: Hospital admitted patients’ laboratory data which includes hematological, biochemical and inflammatory biomarkers were extracted and analyzed. Results: Of 253 COVID-19 patients (218 survivor and 35 non survivor) laboratory findings showed Neutrophilia, lymphocytopenia, raised serum ferritin, C-reactive protein, ESR were observed among large number of the patients. Significantly higher levels of Neutrophil count, decrease lymphocyte count, raised serum ferritin, C-reactive protein, ESR were associated with non-survivor patients compared to survivor patients (all p <0.05). Conclusion: Laboratory investigations of 253 hospitalized COVID-19 cases suggests abnormalities of infection related biomarkers could results fatal outcomes.

Coronavirus disease 2019 (COVID-19), a form of respiratory and systemic zoonosis caused by virus belonging to the Coronaviridae family, originated from town of Wuhan in China, is still spreading around the world thus assuming the dramatic features of a pandemic emergency’. According to the recent statistics of the World Health Organization (WHO), the disease has already involved all continents, with 93.21 million confirmed cases and 2.02 million deaths have been reported until January 19, 20212. In Bangladesh, from the first case identified in early March 2020, 527,632 individuals tested positive for covid-19, and 7,906 died with case fatality rate 1.5% up to 18th January 20217. A recent report suggests that the number of COVID-19 related Although the clinical characteristic of COVID-19 have been broadly defined’, an outline of the most representative laboratory abnormalities found in patients with COVID-2019 infection is still lacking to the best of our knowledge. It was previously highlighted that laboratory medicine plays an essential role in the early detection, diagnosis and management of many diseases’. COVID-2019 makes no exception to this rule, whereby real-time reverse transcription polymerase chain reaction (RT-PCR) enables direct virus identification, whilst detection of anti-COVID-19 antibodies by means of fully- automated immunoassays is the mainstay of serological surveillance’. Nevertheless, the role of laboratory diagnostics extends far beyond etiological diagnosis and epidemiologic surveillance, whereby in vitro diagnostic tests are commonly used for assessing disease severity, for defining the prognosis, for following-up patients, for guiding treatment and for their therapeutic monitoring.